Haleon's Lopsided Quarter Exposes Consumer Healthcare's Portfolio Risk

A cold and flu shortfall

The FTSE 100 consumer healthcare group reported first-quarter revenue of £2.9bn, up just 0.1 per cent on a reported basis, according to its trading statement published on 29 April. Organic revenue growth of 2.2 per cent was driven almost entirely by pricing, which contributed 2.4 percentage points. Volumes fell 0.2 per cent.

The drag came from respiratory and pain relief brands. Haleon described a "weak cold and flu season" that produced a double-digit decline in sales of products including Day Nurse and Theraflu, knocking 1.3 percentage points off overall volume performance in the period, according to the company's filing.

Brian McNamara, Haleon's chief executive, said in the statement: "We delivered a competitive performance in a challenging market, with North America returning to growth and oral health again performing strongly, with innovation and geographic expansion driving double-digit growth in Sensodyne. This was tempered by a weak cold and flu season."

North America returned to growth in the quarter, albeit at just 1 per cent. The company maintained its full-year guidance.

Sensodyne and the India playbook

The standout performer was Sensodyne toothpaste, which posted 10 per cent sales growth in the quarter. The brand's momentum rests on two pillars: product innovation and geographic expansion, particularly in India.

Haleon has pursued a deliberate strategy of selling Sensodyne in smaller, lower-priced packs in India, with package sizes designed to last roughly a week. The approach has made India the second-largest market for Sensodyne behind the United States, according to the company.

The model is increasingly studied across the consumer staples sector. Selling premium brands in smaller formats allows companies to reach price-sensitive consumers in high-growth markets without diluting brand positioning. For Haleon, it has turned oral health into the engine of its growth story at a time when other categories are stalling.

Oral health now carries a disproportionate share of the company's forward momentum. That concentration is a strategic asset when the segment delivers, but it raises questions about what happens if Sensodyne's expansion plateaus or competition intensifies in India's fast-growing oral care market.

Portfolio imbalance: the analyst view

City analysts were direct about the quarter's shortcomings. Chris Beckett, consumer staples analyst at Quilter Cheviot, said: "Haleon has a strong performing asset in Sensodyne toothpaste, which increased sales an impressive 10 per cent."

He added: "The problem for Haleon is that it is only firing on two cylinders and its other categories aren't doing as well as they could or should be doing."

"If everything was sharper, it would add up to a much better growth figure and a more attractive narrative for investors. Haleon isn't a million miles away from being a very good story, but it needs more than the toothpaste business to start performing."

Beckett noted that the long-term tailwinds around consumers increasingly self-medicating remain intact, but argued Haleon's broader brand portfolio should be delivering more.

Shares fell 3 per cent to 341p on the day of the update. They are down more than 5 per cent over the past year, though they remain above the 330p IPO price from July 2022, when Haleon's listing was the largest in Europe for a decade.

The stock's trajectory has not gone unnoticed by short sellers. Hedge fund Marshall Wace disclosed a short position in Haleon in May 2024, when shares were trading near their peak of 419.5p, as first reported at the time. It was the first public bet against the stock. Shares have since fallen roughly 19 per cent from that level.

Haleon's market capitalisation stands at approximately £31bn.

What operators can take from Haleon's quarter

Haleon's mixed results offer several lessons for operators managing consumer brand portfolios.

First, seasonal product lines carry inherent volatility. Cold and flu remedies are high-margin categories, but they are subject to factors entirely outside management's control. A mild winter is not a strategic failure, but it is a structural risk that recurs unpredictably. Any business with significant seasonal exposure needs to model for weak seasons, not just average ones.

Second, the India playbook illustrates how premium brands can be adapted for emerging markets without resorting to separate sub-brands or discounting. Haleon's approach of reducing pack size rather than cutting price per unit preserves the brand's premium positioning while making it accessible. The strategy requires supply chain flexibility and local market knowledge, but it offers a template that extends well beyond toothpaste.

Third, portfolio diversification only works if the portfolio is genuinely diversified in terms of demand drivers. Haleon's brands span oral health, vitamins, pain relief, and respiratory care, but several of those categories are correlated with the same seasonal and macroeconomic factors. True diversification would require exposure to categories with different demand cycles.

Haleon was spun out of GSK (LSE: GSK) in 2022, ending a multi-billion dollar joint venture with Pfizer that had been launched in 2018. The demerger was intended to unlock value by creating a focused consumer healthcare business. Four years on, the question is whether that focus has become a constraint. A company built around over-the-counter remedies and oral care needs both halves of its portfolio to perform. One quarter does not define a strategy, but Haleon's first three months of 2026 suggest the balance has not yet been struck.